Completed PHASE1 INTERVENTIONAL 2-arm NCT05106309

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations Under Fasted and Fed Conditions in Healthy Participants

Sponsor: Cerevel Therapeutics, LLC

Conditions Schizophrenia

Interventions 10 mg CVL-231 as IR formulation 30 mg CVL-231 Target Release, Fasted 30 mg CVL-231 Target Release, Fed 30 mg CVL-231 as fast release MR formulation 30 mg CVL-231 as medium release MR formulation 30 mg CVL-231 as slow-release MR formulation

Updated 6 times since 2021 Last updated: Apr 25, 2022 Started: Dec 29, 2021 Primary completion: Feb 24, 2022 Completion: Feb 24, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Schizophrenia and is currently completed. Cerevel Therapeutics, LLC leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2022 — May 2022 [monthly]

Recruiting PHASE1
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cerevel Therapeutics, LLC

Data source: Cerevel Therapeutics, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States